Section 5 of 6
Economic information and modeling report
20 evidence topics · 16 sources
Modeling overview
Summary
- Barzolvolimab has no published price and no budget impact model; a BLA submission is anticipated in 2027.
- Comparator prices: remibrutinib $4,521 per 30-day supply (60 tablets) as of January 7, 2026; dupilumab $4,193.03 per 4-week supply as of January 1, 2026; omalizumab approximately $30,000 - $60,000 annually at list price (WAC) per Genentech and approximately $1472.76 per unit at the end of 2025 per the Oregon PDAB review. The Oregon PDAB review lists 2025 WACs per 30-day supply of $5,891 for omalizumab 600 mg every 1 month and $3,993 for dupilumab 300 mg every 2 weeks.
- Omalizumab biosimilar competition became available in 2026, and a negotiated Medicare Maximum Fair Price for Xolair is scheduled to take effect January 1, 2028.
- Published cost-effectiveness analyses of comparators report ICERs for omalizumab of £27,469 per QALY gained (NICE TA339, with the patient access scheme), £3183 (UK societal, Novartis-funded), €17 502 per QALY gained (Netherlands societal), and ¥160,411/QALY (China, patient perspective); a US poster reports $3,208,966 per QALY over 10 years for remibrutinib with cetirizine. NICE draft guidance of September 2026 states that remibrutinib should not be used for CSU inadequately controlled by H1-antihistamines in adults. No dupilumab cost-effectiveness analysis in CSU was found.
- The UK omalizumab model assigns utilities from 0.712 for UAS7 = 28–42 to 0.897 for UAS7 = 0.
- Celldex states a prevalence of 0.5-1.0% of the total population, or up to approximately 1 to 3 million patients in the United States.
Remibrutinib list price per 30-day supply, January 2026
Dupilumab wholesale acquisition cost per 4-week supply, January 2026
Omalizumab annual list price range
Omalizumab unit wholesale acquisition cost at the end of 2025 and annual increase since 2019
Wholesale acquisition cost per 30-day supply of omalizumab and dupilumab in 2025
| Product | Quoted dosage and frequency | Quoted year | Quoted WAC per 30-day supply |
|---|---|---|---|
| Omalizumab (Xolair) | “600 mg every 1 month” | “2025” | “$5,891” |
| Dupilumab (Dupixent) | “300 mg every 2 weeks” | “2025” | “$3,993” |
Omalizumab biosimilar competition and Medicare price negotiation
Omalizumab: UK list price and company ICERs with the patient access scheme
Omalizumab: recommendation restricted to severe CSU with a stopping rule
Omalizumab versus standard of care: UK societal cost-utility model, Novartis-funded
“The aim of this study was to assess the cost utility of add-on omalizumab treatment compared with standard of care (SOC) in moderate or severe CSU patients with inadequate response to SOC, from the UK societal perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Model cycle length was 4 weeks, and total model time horizon was 20 years in the base case.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With a deterministic ICER of £3183 in the base case, omalizumab was associated with increased costs and benefits relative to SOC. Probabilistic sensitivity analysis supported this result. Productivity inputs were key model drivers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This research was funded by Novartis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-state utilities by UAS7 band in the UK omalizumab model
| Health state | Quoted UAS7 band | Quoted utility value (SD; distribution) |
|---|---|---|
| Severe urticaria | “UAS7 = 28–42”View highlighted excerpt for this quote | “0.712 (0.31; Beta)”View highlighted excerpt for this quote |
| Moderate urticaria | “UAS7 = 16–27”View highlighted excerpt for this quote | “0.782 (0.26; Beta)”View highlighted excerpt for this quote |
| Mild urticaria | “UAS7 = 7–15”View highlighted excerpt for this quote | “0.845 (0.24; Beta)”View highlighted excerpt for this quote |
| Well-controlled urticaria | “UAS7 = 1–6”View highlighted excerpt for this quote | “0.859 (0.24; Beta)”View highlighted excerpt for this quote |
| Urticaria-free | “UAS7 = 0”View highlighted excerpt for this quote | “0.897 (0.25; Beta)”View highlighted excerpt for this quote |
Omalizumab versus standard of care: Netherlands societal perspective
Omalizumab versus standard treatment: China, patient perspective
“However, the economics of omalizumab treatment relative to standard therapies remains unknown in China.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ICER of omalizumab treatment relative to standard treatment was ¥160,411/QALY, which was between 1 and 3 times GDP per capita.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The purpose of this study was to analyze the cost-effectiveness of omalizumab versus standard treatments for CSU after omalizumab’s inclusion in the National Drug Insurance List from the patient’s perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remibrutinib with cetirizine versus cetirizine alone: US healthcare sector model
Remibrutinib: NICE draft guidance, September 2026
Remibrutinib coverage and workplace productivity: Canadian prevalence-based model
Dupilumab cost-effectiveness analysis in CSU
No evidence found.
Routine laboratory screening versus no testing in adults with CSU: Markov cost-effectiveness model
“A Markov model using cohort analysis and microsimulations was created for adult patients aged 20 years, over a 10-year time horizon, randomized to receive screening laboratory testing or a no-testing approach.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Screening tests were not cost-effective, with ICERs of $856,905 (no therapy), $855,764 (antihistamine therapy), $847,483 (cyclosporine), and $627,318 (omalizumab).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Omalizumab biosimilar: budget impact model across 23 European countries
“A biosimilar market share uptake-based budget impact model (BIM) was developed in Microsoft Excel to compare two scenarios over 5 years: one without biosimilar introduction and one with gradual adoption.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Omalizumab, a monoclonal antibody indicated for severe persistent allergic asthma, chronic spontaneous urticaria (CSU), and chronic rhinosinusitis with nasal polyps (CRSwNP), imposes a financial burden on European healthcare systems due to its high cost, with expenditures exceeding €787 million across 23 countries in 2024.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Introducing an omalizumab biosimilar is projected to save €40 million in the first year at a 30% discounted price compared with using only the originator across 23 countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Company statement of CSU prevalence and US patient numbers
Company statements on the second-line advanced therapy market, angioedema, and severe disease
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.